Patents Assigned to CHILDREN'S HEALTHCARE OF ATLANTA, INC.
  • Publication number: 20190314506
    Abstract: Compositions and methods are described for a polymer hydrogel created by a cycloaddition reaction between an azide and an alkyne that proceeds rapidly without catalyst to produce the polymer hydrogel in less than ninety seconds. The polymer hydrogel can be used in in vivo applications for the localized delivery of therapeutic agent in aqueous solutions. An example of therapeutic delivery of a protein in a mouse model is demonstrated.
    Type: Application
    Filed: July 3, 2018
    Publication date: October 17, 2019
    Applicants: Georgia Tech Research Corporation, Children's Healthcare of Atlanta, Inc.
    Inventors: Niren Murthy, Christopher Hermann, David Scott Wilson, Xinghai Ning, Barbara D. Boyan, Zvi Schwartz, Robert Guldberg, Tamim Diab
  • Patent number: 10421786
    Abstract: This disclosure relates to peptides useful for targeting inflamed or distressed tissue and uses related thereto. In certain embodiment, the peptides comprise SEQ ID NO: 1-14, or variants or derivatives thereof. In certain embodiments, peptides disclosed herein are conjugated to a label to detect, measure, or image cardiac tissue useful in the diagnosis of myocarditis. In certain embodiments, the peptides are conjugated to a particle coating for use in ultrasound imaging, MRI, or targeted therapy. In certain embodiments, peptides disclosed herein are conjugated to a drug or a particle containing a drug useful for targeted therapy.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: September 24, 2019
    Assignees: Emory University, Children's Healthcare of Atlanta, Inc.
    Inventors: Michael Davis, Mario Martinez
  • Patent number: 10393736
    Abstract: This disclosure relates to polymer coatings with desirable anti-fouling properties. In certain embodiments, polymers are coated on particles which allow for conjugation with targeting moieties. In certain embodiments, the particles are nanoparticles with targeting moieties that bind with tumor associated antigens.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: August 27, 2019
    Assignees: Emory University, Children's Healthcare of Atlanta, Inc.
    Inventors: Hui Mao, Yuancheng Li, Lily Yang
  • Patent number: 10392598
    Abstract: This disclosure relates to methods of detecting and quantifying low concentrations of cells in a sample with targeted nanoparticles having Raman reporters using surface-enhanced Raman scattering for detection. In certain embodiments, the sample is a group of cells derived from stem cells that have been differentiated into specific cell types and one is detecting residual stem cells or other progeny in order to quantify the purity of the sample. In certain embodiments, the targeted nanoparticles contain two or more Raman reporters for the purpose of multiplexing. In certain embodiments, purity measurements are used to make quality control determinations.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: August 27, 2019
    Assignees: Emory University, Children's Healthcare of Atlanta, Inc.
    Inventors: Chunhui Xu, Shuming Nie, Jingjia Han
  • Patent number: 10322145
    Abstract: The present disclosure is generally related to methods for combining chemotherapy and immunotherapy for the treatment of a cancer. The methods also relate to generating a drug-resistant cytotoxic immune cell line and uses thereof in conjunction with cytotoxic drugs.
    Type: Grant
    Filed: May 21, 2014
    Date of Patent: June 18, 2019
    Assignees: Emory University, The UAB Research Foundation, Children's Healthcare of Atlanta, Inc.
    Inventors: Harold Trent Spencer, Anindya Dasgupta, Lawrence S. Lamb
  • Patent number: 10227569
    Abstract: In certain embodiments, the disclosure relates to vectors containing bacterial nucleic acid sequences and a paramyxovirus gene. Typically, the expression vector comprises a bacterial artificial chromosome (BAC), and a nucleic acid sequence comprising a respiratory syncytial virus (RSV) gene in operable combination with a regulatory element and optionally a reporter gene.
    Type: Grant
    Filed: April 11, 2012
    Date of Patent: March 12, 2019
    Assignees: EMORY UNIVERSITY, CHILDREN'S HEALTHCARE OF ATLANTA, INC.
    Inventors: Martin L. Moore, Anne Hotard
  • Patent number: 10168341
    Abstract: A device may be configured to allow individual measuring of at least one property of at least one cell, such as measuring a contraction force of a platelet. The device may include a plurality of wells. Each well may include a hydrogel layer, the hydrogel layer including a hydrogel having a top surface that includes a pattern of cell interaction regions. The wells may differ in stiffness properties of the hydrogel and/or biochemical conditions. Each cell interaction region may include a group of at least two cell interaction sites. The spacing between each cell interaction region may be greater than a spacing between the at least two cell interaction sites of each cell interaction region. In this way, cell-cell interactions may be reduced and thereby increasing number of individual cells capable of being measured.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: January 1, 2019
    Assignees: Emory University, Children's Healthcare of Atlanta, Inc.
    Inventors: Wilbur A. Lam, David Myers, Yongzhi Qiu
  • Publication number: 20180344877
    Abstract: Disclosed herein are recombinant viral vectors comprising a liver specific promotor in operable combination with a heterologous nucleic acid sequence encoding a protein, such as a clotting factor. Methods of treating a subject with a clotting disorder, such as hemophilia A or hemophilia B, are also provided.
    Type: Application
    Filed: August 8, 2018
    Publication date: December 6, 2018
    Applicants: Emory University, Children's Healthcare of Atlanta, Inc.
    Inventors: Christopher B. Doering, H. Trent Spencer, Harrison C. Brown
  • Patent number: 10093709
    Abstract: In certain embodiments, this disclosure relates to conjugates comprising a polypeptide of GM-CSF and a polypeptide IL-4. Typically, the GM-CSF and IL-4 are connected by a linker, e.g., polypeptide. In certain embodiments, the disclosure relates to isolated nucleic acids encoding these polypeptide conjugates, vectors comprising nucleic acid encoding polypeptide conjugates, and protein expression systems comprising these vectors such as infectious viral particles and host cells comprising such nucleic acids.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: October 9, 2018
    Assignees: Emory University, Children's Healthcare of Atlanta, Inc.
    Inventors: Jacques Galipeau, Jiusheng Deng
  • Patent number: 10081678
    Abstract: This disclosure relates to specific binding agents, such as isolated recombinant monoclonal antibodies, that bind Glycoprotein Ib alpha (GPIba). More specifically, the disclosure relates to methods of preventing platelet ectodomain shedding, preventing platelet clearance and degradation, maintaining and increasing platelet blood serum levels for in vitro or in vivo applications. In some embodiments, the disclosure relates to the production, diagnostic use, and therapeutic use of monoclonal and polyclonal antibodies, and the antigen-binding fragments thereof, which specifically bind GPIba. Aspects of the disclosure also relate to hybridomas or other cell lines expressing such antibodies for specific binding agent. Compositions and methods for inhibiting shedding, clearance, or degradation, or treating diseases associated with GPIba ectodomain shedding are also described.
    Type: Grant
    Filed: February 3, 2014
    Date of Patent: September 25, 2018
    Assignees: Emory University, Children's Healthcare of Atlanta, Inc.
    Inventor: Renhao Li
  • Patent number: 10072058
    Abstract: This disclosure relates to a GM-CSF and IL-4 conjugate fused to a glycolipid (GPI)-anchoring sequence that is incorporated into chimeric virus-like particles (VLPs) enriched with a viral protein, e.g., viral envelope protein or HIV envelope protein. In certain embodiments, the disclosure relates to methods of immunization with the chimeric VLPs disclosed herein. In certain embodiments, the disclosure relates to methods of immunization with disclosed HIV antigen containing VLPs through an intramuscular priming-intranasal boosting immunization route.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: September 11, 2018
    Assignees: Emory University, Children's Healthcare of Atlanta, Inc.
    Inventors: Baozhong Wang, Richard W. Compans, Jacques Galipeau, Jiusheng Deng
  • Publication number: 20180250337
    Abstract: The present disclosure provides novel cell compositions engineered to express at least a chimeric antigen receptor and a survival factor. Methods of using such cell compositions are also described.
    Type: Application
    Filed: September 6, 2016
    Publication date: September 6, 2018
    Applicants: The UAB Research Foundation, Emory University, Children's Healthcare of Atlanta, Inc.
    Inventors: Lawrence S. Lamb, H. Trent Spencer, G. Yancey Gillespie
  • Patent number: 10058624
    Abstract: Disclosed herein are recombinant viral vectors comprising a liver specific promotor in operable combination with a heterologous nucleic acid sequence encoding a protein, such as a clotting factor. Methods of treating a subject with a clotting disorder, such as hemophilia A or hemophilia B, are also provided.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: August 28, 2018
    Assignees: Emory University, Children's Healthcare of Atlanta, Inc.
    Inventors: Christopher B. Doering, H. Trent Spencer, Harrison C. Brown
  • Patent number: 10039831
    Abstract: Compositions and methods are described for a polymer hydrogel created by a cycloaddition reaction between an azide and an alkyne that proceeds rapidly without catalyst to produce the polymer hydrogel in less than ninety seconds. The polymer hydrogel can be used in in vivo applications for the localized delivery of therapeutic agent in aqueous solutions. An example of therapeutic delivery of a protein in a mouse model is demonstrated.
    Type: Grant
    Filed: March 19, 2012
    Date of Patent: August 7, 2018
    Assignees: Georgia Tech Research Corporation, Children's Healthcare of Atlanta, Inc.
    Inventors: Niren Murthy, Christopher Hermann, David Scott Wilson, Xinghai Ning, Barbara D. Boyan, Zvi Schwartz, Robert Guldberg, Tamim Diab
  • Patent number: 10022049
    Abstract: Systems, devices, and methods are described for the assessment, screening, monitoring, or diagnosis of developmental or cognitive conditions, including autism spectrum disorders (ASD) by analysis of eye tracking data generated from feedback received as a result of display of specific predetermined visual stimuli to a subject or patient. Subsequent to a calibration phase, a testing procedure is performed by presenting predetermined stimuli (e.g., videos) to a subject via a display device. Eye tracking data (from the subject moving his or her eyes in response to predetermined movies or other visual stimuli) are collected. During the data collection period, the system periodically presents targets to reflexively elicit the subject's gaze. These data are used to later verify accuracy. Analysis of the subject's viewing patterns during these stimuli is used for the assessment, screening, monitoring, or diagnosis of developmental or cognitive conditions such as ASD.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: July 17, 2018
    Assignee: Children's Healthcare of Atlanta, Inc.
    Inventors: Ami Klin, Warren Jones, Peter Lewis
  • Patent number: 10016156
    Abstract: The present systems and methods provide a mechanism to assess viewer behavior, features of stimuli, and the interaction between viewer behavior and stimuli. The systems and methods described herein for quantifying blink response and blink inhibition provide moment-by-moments measurements of viewer engagement by measuring what is or is not engaging enough to warrant viewers' inhibition of blinking. The present disclosure describes measures of visual scanning, eye movements, blink data, and blink timing data to derive a measure of how engaged a person is with what he or she is looking at. Blink-related data as a measure of viewer engagement provides a mechanism for determining the most engaging spatial and temporal aspects of a stimulus.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: July 10, 2018
    Assignee: Children's Healthcare of Atlanta, Inc.
    Inventors: Ami Klin, Warren Jones, Sarah Shultz
  • Patent number: 9999666
    Abstract: In certain embodiments, this disclosure relates to conjugates comprising GM-CSF and IL-7 and uses related thereto, e.g., enhancing the adaptive immune system. Typically the GM-CSF and IL-7 are connected by a polymer linker, e.g., polypeptide. In certain embodiments, the disclosure relates to nucleic acids encoding these polypeptide conjugates, vectors comprising nucleic acid encoding polypeptide conjugates, and protein expression systems comprising these vectors such as infectious viral particles and host cells comprising such a nucleic acids.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: June 19, 2018
    Assignees: Emory University, Children's Healthcare of Atlanta, Inc.
    Inventors: Jacques Galipeau, Hsiang-Chuan Hsieh
  • Patent number: 9993575
    Abstract: Devices and methods relate to inducing or promoting hemostasis. The hemostasis device may include a support layer having a first surface and an opposing second surface. The device may include a layer, the layer disposed on the first surface. The layer may include a target surface configured to contact a target site. The layer may include a monolayer of about 100% graphene or may include laser-reduced graphene oxide. The device may include a sensor configured to measure a level of hemostasis of the target site. The methods relate to a method of manufacturing a hemostatic device including a monolayer of graphene or a layer of laser-reduced graphene oxide.
    Type: Grant
    Filed: March 4, 2013
    Date of Patent: June 12, 2018
    Assignees: Emory University, Children's Healthcare of Atlanta, Inc.
    Inventors: Wilbur A. Lam, Anton Sidorov, Zhigang Jlang
  • Patent number: 9872834
    Abstract: Liposomes of a size of less than 200 nanometers target tumors and preferentially deliver imipramine blue to tumors, including brain tumors such as gliomas. The imipramine blue decreases the invasiveness of the tumors, and inhibits tumor metastasis. The liposomes include cholesterol and chemically pure phospholipids that are essentially neutral and contain saturated fatty acids of between 16 and 18 carbon atoms, such as distearoylphosphatidyl choline, and can also include one or more pegylated phospholipids, such as DSPE-PEG.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: January 23, 2018
    Assignees: Emory University, Georgia Tech Research Corporation, Children's Healthcare of Atlanta, Inc.
    Inventors: Jennifer M. Munson, Ravi V. Bellamkonda, Jack L. Arbiser
  • Patent number: 9861307
    Abstract: The present systems and methods provide a mechanism to assess viewer behavior, features of stimuli, and the interaction between viewer behavior and stimuli. The systems and methods described herein for quantifying blink response and blink inhibition provide moment-by-moments measurements of viewer engagement by measuring what is or is not engaging enough to warrant viewers' inhibition of blinking. The present disclosure describes measures of visual scanning, eye movements, blink data, and blink timing data to derive a measure of how engaged a person is with what he or she is looking at. Blink-related data as a measure of viewer engagement provides a mechanism for determining the most engaging spatial and temporal aspects of a stimulus.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: January 9, 2018
    Assignee: Children's Healthcare of Atlanta, Inc.
    Inventors: Ami Klin, Warren Jones, Sarah Shultz